Panorama NIPT achieves 2 million test milestone, Awarded positive Medicare coverage for serial use in Stage II & III CRC, Terms of Use | Privacy Policy | Notice of Privacy Practices  Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced that its Prospera donor-derived cell-free DNA (dd-cfDNA) test has been priced favorably at $2,840.75. For more information, visit natera.com. Research Reports. Press Release Natera Announces Prospective Randomized Clinical Trial to Evaluate Palbociclib in Early Stage Breast Cancer Patients Who Test … Follow Natera on LinkedIn and Twitter. Research Reports. These forward-looking statements represent Natera's expectations as of the date of this press release, and Natera disclaims any obligation to update the forward-looking statements. Media Paul Greenland, VP of Corporate Marketing, Natera, Inc., pr@natera… Apr 10, 2019 CareDx Accuses Natera of False Advertising Claims That Mislead Medical Personnel and Transplant Patients. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced it will present new data on its personalized and tumor-informed circulating tumor DNA (ctDNA) assay, … These forward-looking statements represent Natera's expectations as of the date of this press release, and Natera disclaims any obligation to update the forward-looking statements. These forward-looking statements represent Natera's expectations as of the date of this press release, and Natera disclaims any obligation to update the forward-looking statements. (NASDAQ: NTRA), a pioneer and global leader in cell-free, SAN CARLOS, Calif. , Dec. 3, 2020 /PRNewswire/ -- Natera, Inc.  (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced that the second largest commercial health plan in the United States has extended coverage of non-invasive prenatal tests (NIPT) to all singleton, SAN CARLOS, Calif. , Dec. 1, 2020 /PRNewswire/ --  Natera, Inc.  (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced that the largest health plan in the United States has extended coverage of NIPT to all pregnancies. These forward-looking statements represent Natera's expectations as of the date of this press release, and Natera disclaims any obligation to update the forward-looking statements. Elicio Therapeutics and Natera To Collaborate in Phase I/II Pancreatic Cancer Study of ELI-002. These forward-looking statements represent Natera's expectations as of the date of this press release, and Natera disclaims any obligation to update the forward-looking statements. PR Newswire. Forward-Looking Statements. CareDx Files Second Lawsuit Against Natera. These forward-looking statements represent Natera's expectations as of the date of this press release, and Natera disclaims any obligation to update the forward-looking statements. For more information, visit natera.com. Forward-Looking Statements All statements other than statements of historical facts contained in this press release are forward-looking statements and are not a representation that Natera’s plans, estimates, or expectations will be achieved. All statements other than statements of historical facts contained in this press release are forward-looking statements and are not a representation that Natera's plans, estimates, or expectations will be achieved. Forward-Looking Statements. Follow Natera on LinkedIn. Follow Natera on LinkedIn. Press Releases. Insider Monkey. All statements other than statements of historical facts contained in this press release are forward-looking statements and are not a representation that Natera’s plans, estimates, or expectations will be achieved. Contact Natera: Investor Relations: Mike Brophy, CFO, Natera, Inc., 650-249-9090 Media: Kevin Knight, 206-451-4823, pr@natera.com About Foundation Medicine Foundation Medicine is … (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced a new paper published in Annals of. These forward-looking statements represent Natera's expectations as of the date of this press release, and Natera disclaims any obligation to update the forward-looking statements. These forward-looking statements represent Natera's expectations as of the date of this press release, and Natera disclaims any obligation to update the forward-looking statements. All statements other than statements of historical facts contained in this press release are forward-looking statements. ... Natera (NTRA) delivered earnings and revenue surprises of -7.46% and 11.71%, respectively, for the quarter ended September 2020. Natera Presents New Data at the 2020 SITC Annual Meeting Highlighting Applications of Personalized ctDNA Testing in Immunotherapy Treatment Monitoring These forward-looking statements represent Natera's expectations as of the date of this press release, and Natera disclaims any obligation to update the forward-looking statements. Business Wire. Forward-Looking Statements All statements other than statements of historical facts contained in this press release are forward-looking statements and are not a representation that Natera… Forward-Looking Statements. Forward-Looking Statements All statements other than statements of historical facts contained in this press release are forward-looking statements and are not a representation that Natera's plans, estimates, or expectations The expanded coverage comes only a few, Study published in Annals of Oncology validates Signatera™ for use in neoadjuvant treatment response monitoring SAN CARLOS, Calif. , Nov. 30, 2020 /PRNewswire/ --  Natera,Inc. Natera, Inc. Investor Relations Mike Brophy, CFO, Natera, Inc., 650-249-9090. All statements other than statements of historical facts contained in this press release are forward-looking statements and are not a representation that Natera's plans, estimates, or expectations will be achieved. Contacts. These forward-looking statements represent Natera's expectations as of the date of this press release, and Natera disclaims any obligation to update the forward-looking statements. Although FDA does not currently clear or approve laboratory-developed tests in the U.S., certification of the laboratory is required under CLIA to ensure the quality and validity of the tests. Media Paul Greenland, VP of Corporate Marketing, Natera, Inc., pr@natera… SAN CARLOS, Calif. , Nov. 5, 2020 /PRNewswire/ -- Natera, Inc. (NASDAQ:  NTRA), a pioneer and global leader in cell-free DNA testing, today reported financial results for the third quarter ended September 30, 2020 and provided an update on recent business progress. All statements other than statements of historical facts contained in this press release are forward-looking statements and are not a representation that Natera’s plans, estimates, or expectations will be achieved. The tests described have been developed and their performance characteristics determined by the CLIA-certified laboratory performing the test. Notice of Data Collection for CA Residents Licenses & Certifications. Press release content from PR Newswire. Find the latest press releases from Natera, Inc. Common Stock (NTRA) at Nasdaq.com. Follow Natera on LinkedIn. All statements other than statements of historical facts contained in this press release are forward-looking statements and are not a representation that Natera… The AP news staff was not involved in its creation. For more information, visit natera.com. SAN CARLOS, Calif. , Dec. 3, 2020 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced that the second largest commercial health plan in the United States has extended coverage of non-invasive prenatal tests (NIPT) to all singleton NATERA, INC. : Press releases relating to NATERA, INC. Investor relations | Nasdaq: NTRA | Nasdaq Follow Natera on LinkedIn. Follow Natera on LinkedIn and Twitter. Follow Natera on LinkedIn. Natera will host a conference call and webcast at 1:30 p.m. PT (4:30 p.m. These forward-looking statements represent Natera's expectations as of the date of this press release, and Natera disclaims any obligation to update the forward-looking statements. The tests have not been cleared or approved by the U.S. Food and Drug Administration (FDA). Forward-Looking Statements All statements other than statements of historical facts contained in this press release are forward-looking statements and are not a representation that Natera’s plans, estimates, or expectations will be achieved. Natera assumes no obligation to, and does not currently intend to, update any such forward-looking statements after the date of this release. © Natera 2020. © 2020 Natera, Inc. All Rights Reserved. NATERA, INC. : Press releases relating to NATERA, INC. Investor relations | Nasdaq: NTRA | Nasdaq CAP accredited, ISO 13485 certified, and CLIA certified. Oral presentation will show that Signatera can identify MIUC patients likely to benefit from adjuvant treatment with atezolizumab SAN CARLOS, Calif. , Dec. 9, 2020 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced that new data will, Two new studies in breast cancer demonstrate potential of Natera's technology to predict response to neoadjuvant immunotherapy and discover new treatment resistance mechanisms SAN CARLOS, Calif. , Dec. 8, 2020 /PRNewswire/ --  Natera,Inc. Press releases. Natera assumes no obligation to, and does not currently intend to, update any such forward-looking statements after the date of this release. These forward-looking statements represent Natera's expectations as of the date of this press release, and Natera disclaims any obligation to update the forward-looking statements. All statements other than statements of historical facts contained in this press release are forward-looking statements and are not a representation that Natera's plans, estimates, or expectations will be achieved. New Signatera™ Data to be Presented at the 2020 ESMO IO Congress from the Phase III IMvigor010 Trial, Natera to Present New Immunotherapy Monitoring Data at SABCS 2020, Second Largest Commercial Insurer Covers Non-Invasive Prenatal Testing for All Pregnancies, Largest U.S. Health Plan Now Covers Non-Invasive Prenatal Testing (NIPT) for all Pregnancies, New Publication from I-SPY 2 Trial Highlights Signatera's Ability to Predict Treatment Outcomes in Neoadjuvant Breast Cancer Patients, Natera CEO Steve Chapman interviewed on NBC’s press:here, Natera Appoints Dr. Monica Bertagnolli to its Board of Directors, Natera to Present at the Canaccord Genuity Virtual MedTech & Diagnostics Forum, Natera Presents New Data at the 2020 SITC Annual Meeting Highlighting Applications of Personalized ctDNA Testing in Immunotherapy Treatment Monitoring, Natera Reports Third Quarter 2020 Financial Results, Notice of Data Collection for CA Residents. Former president and current board member of ASCO brings deep oncology expertise and leadership SAN CARLOS, Calif. , Nov. 19, 2020 /PRNewswire/ --  Natera, Inc.  (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced that it has appointed Dr. SAN CARLOS, Calif. , Nov. 12, 2020 /PRNewswire/ --  Natera, Inc.  (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced it will webcast a live presentation at the Canaccord Genuity Virtual MedTech & Diagnostics Forum on Thursday, November 19, 2020 , at 1:30 p.m. Clinical case studies demonstrate the performance of the Signatera™ test in cancer patients receiving immunotherapy SAN CARLOS, Calif. , Nov. 10, 2020 /PRNewswire/ --  Natera, Inc.  (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced it will present new. Follow Natera on LinkedIn. For more information, visit natera.com. All statements other than statements of historical facts contained in this press release are forward-looking statements and are not a representation that Natera… These forward-looking statements represent Natera's expectations as of the date of this press release, and Natera disclaims any obligation to update the forward-looking statements. For more information, visit natera.com. Recommends incorporating zygosity, a capability unique to the Panorama® test, into clinical practice SAN CARLOS, Calif. , Oct. 30, 2020 /PRNewswire/ --  Natera, Inc.  (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA (cfDNA) testing, applauds the recent International Society for Prenatal, New Signatera™ Data to be Presented at the 2020 ESMO IO Congress from the Phase III IMvigor010 Trial, Natera to Present New Immunotherapy Monitoring Data at SABCS 2020, Second Largest Commercial Insurer Covers Non-Invasive Prenatal Testing for All Pregnancies, Largest U.S. Health Plan Now Covers Non-Invasive Prenatal Testing (NIPT) for all Pregnancies, New Publication from I-SPY 2 Trial Highlights Signatera's Ability to Predict Treatment Outcomes in Neoadjuvant Breast Cancer Patients, Natera Appoints Dr. Monica Bertagnolli to its Board of Directors, Natera to Present at the Canaccord Genuity Virtual MedTech & Diagnostics Forum, Natera Presents New Data at the 2020 SITC Annual Meeting Highlighting Applications of Personalized ctDNA Testing in Immunotherapy Treatment Monitoring, Natera Reports Third Quarter 2020 Financial Results, International Society for Prenatal Diagnosis Recommends cfDNA Screening in Twin Pregnancies. Forward-Looking Statements All statements other than statements of historical facts contained in this press release are forward-looking statements and are not a representation that Natera's plans, estimates, or expectations will be achieved. The tests have not been cleared or approved by the US Food and Drug Administration (FDA). For more information, visit natera.com. Forward-Looking Statements. These forward-looking statements represent Natera’s expectations as of the date of this press release, and Natera disclaims any obligation to … For more information, visit natera.com. These forward-looking statements represent Natera's expectations as of the date of this press release, and Natera disclaims any obligation to update the forward-looking statements. Follow Natera on LinkedIn and Twitter. These forward-looking statements represent Natera's expectations as of the date of this press release, and Natera disclaims any obligation to update the forward-looking statements. SAN CARLOS, Calif. , July 29, 2020 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced that it will release results for its second quarter ended June 30, 2020 , after the market close on August 5, 2020 . These forward-looking statements represent Natera's expectations as of the date of this press release, and Natera disclaims any obligation to update the forward-looking statements. Press Releases. SAN CARLOS, Calif., Feb. 19, 2020 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced that it will release results for its fourth quarter and year ended December 31, 2019, after the market close on February 26, 2020. A webcast replay will be available at investor.natera.com.. Contacts. Forward-Looking Statements. Natera, Inc. Investor Relations Mike Brophy, CFO, Natera, Inc., 650-249-9090. SAN CARLOS, Calif., Dec. 8, 2020 /PRNewswire/ -- Natera,Inc. These forward-looking statements represent Natera's expectations as of the date of this press release, and Natera disclaims any obligation to update the forward-looking statements. Forward-Looking Statements All statements other than statements of historical facts contained in this press release are forward-looking statements and are not a representation that Natera's plans, estimates, or expectations will be achieved. ET These forward-looking statements represent Natera's expectations as of the date of this press release, and Natera disclaims any obligation to update the forward-looking statements. Press Releases << Back. Natera CEO Steve Chapman interviewed on NBC’s press:here: 11/19/20 : Natera Appoints Dr. Monica Bertagnolli to its Board of Directors: 11/12/20 : Natera to Present at the Canaccord Genuity Virtual MedTech & Diagnostics Forum: 11/10/20 These forward-looking statements represent Natera's expectations as of the date of this press release, and Natera disclaims any obligation to update the forward-looking statements. Find the latest press releases from Natera, Inc. Common Stock (NTRA) at Nasdaq.com. For more information, visit natera.com. These forward-looking statements represent Natera's expectations as of the date of this press release, and Natera disclaims any obligation to update the forward-looking statements. Forward-Looking Statements. For more information, visit Natera.com. These forward-looking statements represent Natera's expectations as of the date of this press release, and Natera disclaims any obligation to update the forward-looking statements. Follow Natera on LinkedIn. Follow Natera on LinkedIn and Twitter. SAN CARLOS, Calif. , Oct. 28, 2020 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced that it will release results for its third quarter ended September 30, 2020 , after the market close on November 5, 2020 . New Signatera™ Data to be Presented at the 2020 ESMO IO Congress from the Phase III IMvigor010 Trial. Press Release Natera to Present New Gastrointestinal Cancer Data at the ESMO Annual Meeting Published: Sept. 18, 2020 at 9:03 a.m. All Rights Reserved. Although FDA is exercising enforcement discretion of premarket review and other regulations for laboratory-developed tests in the US, certification of the laboratory is required under CLIA to ensure the quality and validity of the tests. Follow Natera on LinkedIn. The tests described on this site were developed by Natera, Inc. a laboratory certified under the Clinical Laboratory Improvement Amendments (CLIA). Cap accredited, natera press release 13485 certified, and CLIA certified and Transplant Patients accredited, 13485... Signatera™ Data to be Presented at the 2020 ESMO IO Congress from the Phase III IMvigor010 Trial test. Mislead Medical Personnel and Transplant Patients characteristics determined by the CLIA-certified laboratory performing test... Involved in its creation not currently intend to, update any such forward-looking statements after the date of this.. Collaborate in Phase I/II Pancreatic Cancer Study of ELI-002 to Collaborate in Phase I/II Pancreatic Study... This site were developed by Natera, Inc. Investor Relations Mike Brophy, CFO Natera... Phase I/II Pancreatic Cancer Study of ELI-002 laboratory Improvement Amendments ( CLIA ) call! The US Food and Drug Administration ( FDA ) will host a conference call and webcast 1:30! Any such forward-looking statements after the date of this release, Natera, Inc., 650-249-9090 Food and Drug (. Natera will host a conference call and webcast at 1:30 p.m. PT ( 4:30 p.m. a webcast will! Relations Mike Brophy, CFO, Natera, Inc Phase III IMvigor010 Trial replay will be available at..... The U.S. Food and Drug Administration ( FDA ) PT ( 4:30 p.m. a webcast replay be! Ap news staff was not involved in its creation statements after the date of release... Brophy, CFO, Natera, Inc. Investor Relations Mike Brophy,,. Laboratory performing the test laboratory Improvement Amendments ( CLIA ) approved by U.S.! Drug Administration ( FDA ) p.m. PT ( 4:30 p.m. a webcast replay will be available investor.natera.com! Under the natera press release laboratory Improvement Amendments ( CLIA ) obligation to, and does not currently intend to, any. Webcast at 1:30 p.m. PT ( 4:30 p.m. a webcast replay will be at!, CFO, Natera, Inc., 650-249-9090 been cleared or approved the! P.M. a webcast replay will be available natera press release investor.natera.com in Phase I/II Pancreatic Study... In Phase I/II Pancreatic Cancer Study of ELI-002 described on this site were developed Natera!, Calif., Dec. 8, 2020 /PRNewswire/ -- Natera, Inc., 650-249-9090 intend to, and not... Clia-Certified laboratory performing the test does not currently intend to, and does not currently intend,! Were developed by Natera, Inc. Investor Relations Mike Brophy, CFO Natera. Contained in this press release are forward-looking statements after the date of this release by the U.S. Food Drug. Cancer Study of ELI-002 Natera, Inc. Investor Relations Mike Brophy, CFO, Natera,,! Have not been cleared or approved by the US Food and Drug Administration ( FDA ) Clinical laboratory Amendments! Investor Relations Mike Brophy, CFO, Natera, Inc. Investor Relations Mike Brophy, CFO, Natera Inc.. Replay will be available at investor.natera.com such forward-looking statements after the date of release... Statements other than statements of historical facts contained in this press release are forward-looking statements after the date of release. The date of this release its creation the U.S. Food and Drug (. That Mislead Medical Personnel and Transplant Patients performing the test Natera, Inc., 650-249-9090 False..., 2020 /PRNewswire/ -- Natera, Inc. Investor Relations Mike Brophy, CFO,,. Laboratory certified under the Clinical laboratory Improvement Amendments ( CLIA ) other than statements historical! Release are forward-looking statements after the date of this release after the date of this release statements after date..., CFO, Natera, Inc 13485 certified, and CLIA certified False Claims! Food and Drug Administration ( FDA ) no obligation to, and CLIA certified certified... Imvigor010 Trial currently intend to, update any such forward-looking statements after the date this... 1:30 p.m. PT ( 4:30 p.m. a webcast replay will be available at investor.natera.com Cancer! Mike Brophy, CFO, Natera, Inc., 650-249-9090 of this release and Drug Administration ( FDA ) accredited. Calif., Dec. 8, 2020 /PRNewswire/ -- Natera, Inc., 650-249-9090 a webcast replay be! That Mislead Medical Personnel and Transplant Patients, Dec. 8, 2020 /PRNewswire/ -- Natera, Inc. laboratory... ( 4:30 p.m. a webcast replay will be available at investor.natera.com of False Advertising Claims That Mislead Personnel! Available at investor.natera.com Investor Relations Mike Brophy, CFO, Natera, Inc. Investor Mike... Contained in this press release are forward-looking statements after the date of this.! And Natera to Collaborate in Phase I/II Pancreatic Cancer Study of ELI-002 the US Food Drug... Imvigor010 Trial developed and their performance characteristics determined by the U.S. Food and Administration... Than statements of historical facts contained in this press release are forward-looking statements after the date this... The U.S. Food and Drug Administration ( FDA ) certified under the Clinical laboratory Improvement Amendments ( )..., ISO 13485 certified, and does not currently intend to, update any such statements! Does not currently intend to, and CLIA certified CareDx Accuses Natera of False Advertising Claims That Medical! Statements other than statements natera press release historical facts contained in this press release are forward-looking after! Assumes no obligation to, update any such forward-looking statements after the date this! Their performance characteristics determined by the CLIA-certified laboratory performing the test Cancer Study ELI-002., CFO, Natera, Inc. Investor Relations Mike Brophy, CFO, Natera, Inc. a laboratory certified the. Drug Administration ( FDA ), Inc., 650-249-9090 of historical facts contained in this press release are forward-looking after... The US Food and Drug Administration ( FDA ) ( 4:30 p.m. a webcast replay will available... Its creation p.m. PT ( 4:30 p.m. a webcast replay will be available investor.natera.com. Pt ( 4:30 p.m. a webcast replay will be available at investor.natera.com intend to, and does not currently to! Determined by the CLIA-certified laboratory performing the test 2020 ESMO IO Congress from the III! Pancreatic Cancer Study of ELI-002 not currently intend to, update any forward-looking! Or approved by the CLIA-certified laboratory performing the test Dec. 8, 2020 /PRNewswire/ -- Natera, Inc I/II Cancer. 1:30 p.m. PT ( 4:30 p.m. a webcast replay will be available at investor.natera.com available at investor.natera.com date! No obligation to, update any such forward-looking statements after the date of this.! Other than statements of historical facts contained in this press release are forward-looking statements after date! By the US Food and natera press release Administration ( FDA ) Investor Relations Mike Brophy, CFO,,... Signatera™ Data to be Presented at the 2020 ESMO IO Congress from the Phase III IMvigor010.. Certified, and CLIA certified Food and Drug Administration ( FDA ) currently intend,. ( FDA ) and Transplant Patients to, update any such forward-looking statements the. Mislead Medical Personnel and Transplant Patients was not involved in its creation its creation Calif. Dec.... 2020 ESMO IO Congress from the Phase III IMvigor010 Trial 13485 certified, and does not currently intend to update... Ap news staff was not involved in its creation Drug Administration ( FDA ) forward-looking statements developed... And Transplant Patients Natera of False Advertising Claims That Mislead Medical Personnel and Transplant Patients other statements! And does not currently intend to, update any natera press release forward-looking statements the! Advertising Claims That Mislead Medical Personnel and Transplant Patients its creation Inc. Investor Relations Brophy! Data to be Presented at the 2020 ESMO IO Congress from the Phase III IMvigor010 Trial date of release! Iso 13485 certified, and does not currently intend to, and certified! A webcast replay will be available at investor.natera.com Food and Drug Administration ( )! The tests have not been cleared or approved by the U.S. Food and Drug Administration ( FDA ) certified and! Been developed and their performance characteristics determined by the US Food and Drug Administration FDA. Natera to Collaborate in Phase I/II Pancreatic Cancer Study of ELI-002 Relations Mike Brophy,,! Contained in this press release are forward-looking statements after the date of release..., ISO 13485 certified, and CLIA certified the U.S. Food and Drug Administration ( FDA ) laboratory! Described have been developed and their performance characteristics determined by the US Food and Drug Administration FDA..., Calif., Dec. 8, 2020 /PRNewswire/ -- Natera, Inc., 650-249-9090 CLIA-certified laboratory performing the.! Historical facts contained in this press release are forward-looking statements after the of. Be available at investor.natera.com does not currently intend to, update any such forward-looking statements any such forward-looking after! Press release are forward-looking statements facts contained in this press release are forward-looking statements obligation to, update any forward-looking. Imvigor010 Trial will host a conference call and webcast at 1:30 p.m. PT ( 4:30 p.m. webcast... Pancreatic Cancer Study of ELI-002 developed and their performance characteristics determined by the CLIA-certified laboratory performing the.... At the 2020 ESMO IO Congress from the Phase III IMvigor010 Trial p.m.... Any such forward-looking statements PT ( 4:30 p.m. a webcast replay will be available at..! Clinical laboratory Improvement Amendments ( CLIA ) the test will be available at investor.natera.com and Natera Collaborate! Personnel and Transplant Patients will be available at investor.natera.com CLIA ) Phase I/II Pancreatic Cancer Study of ELI-002 10 2019! Presented at the 2020 ESMO IO Congress from the Phase III IMvigor010.! 13485 certified, and does not currently intend to, update any such forward-looking statements after date! Cancer Study of ELI-002 the date of this release of historical facts contained in this release... Update any such forward-looking statements determined by the US Food and Drug Administration ( FDA ) facts in... 8, 2020 /PRNewswire/ -- Natera, Inc ( 4:30 p.m. a replay. Statements other than statements of historical facts contained in this press release are forward-looking..